Patents by Inventor Allen T. Hopper

Allen T. Hopper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHOSPHODIESTERASE 4 INHIBITORS
    Publication number: 20080139583
    Abstract: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.
    Type: Application
    Filed: February 5, 2008
    Publication date: June 12, 2008
    Inventors: Ashok Tehim, Allen T. HOPPER, Ruiping Liu, Hans-Jurgen Ernst Hess, Yajing Rong
  • Phosphodiesterase 4 inhibitors
    Patent number: 7335654
    Abstract: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: February 26, 2008
    Assignee: Memory Pharmaceuticals Corporation
    Inventors: Allen T. Hopper, Ruiping Liu
  • Phosphodiesterase 4 inhibitors
    Patent number: 7332486
    Abstract: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: February 19, 2008
    Assignee: Memory Pharmaceuticals Corp.
    Inventors: Ashok Tehim, Allen T. Hopper, Ruiping Liu, Hans-Jurgen Ernst Hess, Yajing Rong
  • Heterocyclic compounds, methods for the preparation thereof, and uses thereof
    Patent number: 7244745
    Abstract: The compounds of the present invention are of formula I: wherein A, R3, R4 is as defined herein, are useful as ligands for nicotinic receptors.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: July 17, 2007
    Assignee: Memory Pharmaceuticals Corp.
    Inventors: Brian Herbert, Wenge Xie, Truc Minh Nguyen, Allen T Hopper, Ashok Tehim
  • Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
    Patent number: 7153871
    Abstract: PDE4 inhibition is achieved by novel compounds, e.g., aminoindazole and aminobenzofuran analogs. The compounds of the present invention are of Formulas I and II: wherein R1, R2, R3, R4, R7 and R8 are as defined herein.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: December 26, 2006
    Assignee: Memory Pharmaceuticals Corporation
    Inventors: Richard A. Schumacher, Allen T. Hopper, Ashok Tehim
  • Phosphodiesterase 4 inhibitors
    Patent number: 7087625
    Abstract: PDE4 inhibition is achieved by novel nitroxide compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formulas I–III: wherein A, B, D, R1, R2, R3, R7, R8, R9, R10 and R6are as defined herein.
    Type: Grant
    Filed: November 19, 2003
    Date of Patent: August 8, 2006
    Assignee: Memory Pharmaceuticals Corporation
    Inventors: Richard A. Schumacher, Elizabeth Doorly Graham, Allen T. Hopper, Ashok Tehim
  • Heterocyclic compounds, methods for the preparation thereof, and uses thereof
    Publication number: 20040229868
    Abstract: The compounds of the present invention are of formula I: 1
    Type: Application
    Filed: August 29, 2003
    Publication date: November 18, 2004
    Applicant: MEMORY PHARMACEUTICALS CORP.
    Inventors: Brian Herbert, Wenge Xie, Truc Minh Nguyen, Allen T. Hopper, Ashok Tehim
  • Phosphodiesterase 4 inhibitors
    Publication number: 20040152902
    Abstract: PDE4 inhibition is achieved by novel nitroxide compounds, e.g., N-substituted aniline and diphenylamine analogs.
    Type: Application
    Filed: November 19, 2003
    Publication date: August 5, 2004
    Inventors: Richard A. Schumacher, Elizabeth Doorly Graham, Allen T. Hopper, Ashok Tehim
  • Phosphodiesterase 4 inhibitors
    Publication number: 20040102460
    Abstract: PDE4 inhibition is achieved by novel compounds of the Formula I: 1
    Type: Application
    Filed: August 8, 2003
    Publication date: May 27, 2004
    Applicant: MEMORY PHARMACEUTICALS CORP.
    Inventors: Allen T. Hopper, Ruiping Liu
  • Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs memory 29
    Publication number: 20040087584
    Abstract: PDE4 inhibition is achieved by novel compounds, e.g., aminoindazole and aminobenzofuran analogs.
    Type: Application
    Filed: July 18, 2003
    Publication date: May 6, 2004
    Applicant: MEMORY PHARMACEUTICALS CORP.
    Inventors: Richard A. Schumacher, Allen T. Hopper, Ashok Tehim
  • GlyT-1 inhibitors
    Patent number: 6667336
    Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: December 23, 2003
    Assignees: NPS Allelix Corp., Allelix Neuroscience, Inc.
    Inventors: Zhaoqing Wang, William Delaney, Ashok Tehim, Shawn Maddaford, Ian Egle, Richard Schumacher, Allen T. Hopper
  • GLYT-1 INHIBITORS
    Publication number: 20030176489
    Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: 1
    Type: Application
    Filed: February 15, 2002
    Publication date: September 18, 2003
    Inventors: Zhaoqing Wang, William Delaney, Ashok Tehim, Shawn Maddaford, Ian Egle, Richard Schumacher, Allen T. Hopper
  • Pharmaceutical methods of use of 5-substituted and 5,5 disubstituted-3,4-dihydroxy-2(5H)-furanones
    Patent number: 6262073
    Abstract: The present invention relates to synthetic methods for the production of both optically active and racemic 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones; 5-[(4-aryl)-3-butynyl]-3,4-dihydroxy-2(5H)-furanones; 5-(2-arylthio)ethyl-3,4-dihydroxy-2(5H)-furanones; and 5-(2-aryloxy)ethyl-3,4-dihydroxy-2(5H)-furanones. This invention further relates to the use of the above mentioned compounds as anti-inflammatory agents through their action as mixed inhibitors of lipid peroxidation, 5-lipoxygenase, cyclooxygenase-1 and cyclooxygenase-2. The invention further relates to the use of such compounds in the treatment of chronic inflammatory disorders such as asthma, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, acute respiratory distress syndrome, and central nervous system disorders such as Alzheimer's and Parkinson's disease wherein reactive oxygen species and inflammatory mediators are contributing deleterious factors.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: July 17, 2001
    Assignee: Oxis International Inc.
    Inventors: Allen T. Hopper, John A. Ziemniak, Robert E. Johnson
  • 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones and methods of use therefor
    Patent number: 6136832
    Abstract: The present invention relates to synthetic methods for the production of both optically active and racemic 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones; 5-[(4-aryl)-3-butynyl]-3,4-dihydroxy-2(5H)-furanones; 5-(2-arylthio)ethyl-3,4-dihydroxy-2(5H)-furanones; and 5-(2-aryloxy)ethyl-3,4-dihydroxy-2(5H)-furanones. This invention further relates to the use of the above mentioned compounds as anti-inflammatory agents through their action as mixed inhibitors of lipid peroxidation, 5-lipoxygenase, cyclooxygenase-1 and cyclooxygenase-2. The invention further relates to the use of such compounds in the treatment of chronic inflammatory disorders such as asthma, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, acute respiratory distress syndrome, and central nervous system disorders such as Alzheimer's and Parkinson's disease wherein reactive oxygen species and inflammatory mediators are contributing deleterious factors.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: October 24, 2000
    Assignee: Oxis International Inc.
    Inventors: Allen T. Hopper, John A. Ziemniak, Robert E. Johnson
  • Skin protectant comprising 5-substituted and 5,5-disubstituted 3,4-dihydroxy-2(5H)-furanones
    Patent number: 6010685
    Abstract: Formulations of racemic or optically active 3,4-dihydroxy-5-aryl-2(5H)-furanoncs are provided for topical administration to the skin for the inhibition and prevention of sunburn cell formation resulting from exposure to ultraviolet radiation and other sources of damage, and for the treatment of skin aging. The compounds may be formulated in combination with a sunscreen, and may be applied before, during, and/or after exposure.
    Type: Grant
    Filed: March 8, 1999
    Date of Patent: January 4, 2000
    Assignee: Oxis International, Inc.
    Inventors: John A. Ziemniak, Allen T. Hopper, Peter T. Pugliese
  • 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
    Patent number: 6005000
    Abstract: The present invention relates to synthetic methods for the production of both optically active and racemic 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones; 5-[(4-aryl)-3-butynyl]-3,4-dihydroxy-2(5H)-furanones; 5-(2-arylthio)ethyl-3,4-dihydroxy-2(5H)-furanones; and 5-(2-aryloxy)ethyl-3,4-dihydroxy-2(5H)-furanones. This invention further relates to the use of the above mentioned compounds as anti-inflammatory agents through their action as mixed inhibitors of lipid peroxidation, 5-lipoxygenase, cyclooxygenase-1 and cyclooxygenase-2. The invention further relates to the use of such compounds in the treatment of chronic inflammatory disorders such as asthma, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, acute respiratory distress syndrome, and central nervous system disorders such as Alzheimer's and Parkinson's disease wherein reactive oxygen species and inflammatory mediators are contributing deleterious factors.
    Type: Grant
    Filed: August 20, 1997
    Date of Patent: December 21, 1999
    Assignee: Oxis International, Inc.
    Inventors: Allen T. Hopper, John A. Ziemniak, Robert E. Johnson
  • Optically pure 4-aryl-2-hydroxytetronic acids
    Patent number: 5504108
    Abstract: The present invention relates to a method for synthesis of optically pure stereogenically labile 4-aryl-2-hydroxytetronic acids from an optically pure aidehyde. The invention further relates to the use of such optically pure compounds as potent inhibitors of platelet aggregation by working at the level of cyclooxygenase, and additionally as inhibitors of cyclooxygenase and 5-lipoxygenase. The invention further relates to the pharmaceutical use of such.compounds in the treatment of coronary artery diseases, especially in the treatment and/or prevention of atherosclerosis, and in the treatment of various inflammatory pathologies, especially arthritis.
    Type: Grant
    Filed: December 5, 1994
    Date of Patent: April 2, 1996
    Assignee: The Ohio State University Research Foundation
    Inventors: Donald T. Witiak, Allen T. Hopper
  • Synthesis of optically pure 4-aryl-2-hydroxytetronic acids
    Patent number: 5399721
    Abstract: The present invention relates to a method for synthesis of optically pure stereogenically labile 4-aryl-2-hydroxytetronic acids from an optically pure aldehyde. The invention further relates to the use of such optically pure compounds as potent inhibitors of platelet aggregation by working at the level of cyclooxygenase. the invention further relates to the pharmaceutical use of such compounds in the treatment of coronary artery diseases, especially in the treatment and/or prevention of atherosclerosis.
    Type: Grant
    Filed: February 25, 1994
    Date of Patent: March 21, 1995
    Assignee: The Ohio State University Research Foundation
    Inventors: Allen T. Hopper, Donald T. Witiak